This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;301(17):1758.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Scientists from Genentech (South San Francisco, Calif) have discovered a variant of an engineered antibody that can bind 2 proteins involved in cancer.

The researchers isolated a variant of the monoclonal antibody biologic trastuzumab, which binds to the human epidermal growth factor receptor 2 (HER2); this variant also can bind vascular endothelial growth factor (VEGF) (Bostrum J et al. Science. 2009;323[5921]:1610-1614). The scientists visualized the structure of this 2-protein–binding variant using x-ray crystallography. Additionally, they found that a trastuzumab variant with high affinity for both HER2 and VEGF can inhibit cell proliferation mediated by these 2 proteins in a human cell line and inhibit tumor progression mediated by these proteins in a mouse model.

Researchers have found a variant of trastuzumab that can bind both human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF). (Photo credit: Allison Bruce and Jenny Bostrom)

The authors . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?